Published in Br J Cancer on December 01, 2000
Regular review: Managing testicular cancer. BMJ (2001) 1.43
Why does cytotoxic chemotherapy cure only some cancers? Nat Clin Pract Oncol (2008) 1.04
Testicular cancer: a prototypic tumor of young adults. Semin Oncol (2009) 1.01
Update on management of seminoma. Indian J Urol (2010) 0.99
Current management of testicular cancer. Korean J Urol (2013) 0.98
Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer (2004) 0.89
A rare case of advanced testicular seminoma in a 78-year-old man managed successfully with carboplatin based chemotherapy: a case report. Cases J (2008) 0.89
Testicular cancer: seminoma. BMJ Clin Evid (2007) 0.88
Testicular cancer: seminoma. BMJ Clin Evid (2011) 0.80
Good-risk-advanced germ cell tumors: historical perspective and current standards of care. World J Urol (2009) 0.77
Regression of metastatic seminoma in a patient referred for carcinoma of unknown primary origin. Nat Rev Urol (2010) 0.75
Combined management of malignant teratoma of the testis. Lancet (1979) 3.12
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42
Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol (1996) 1.85
Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol (1989) 1.68
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer (1997) 1.55
Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol (1989) 1.46
Combination chemotherapy in germinal cell tumors. Cancer Treat Rev (1976) 1.38
Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol (1994) 1.33
Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol (1995) 1.16
Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol (1989) 1.14
Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer (1997) 1.09
Chemotherapy of disseminated seminoma. Cancer Clin Trials (1980) 0.97
Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy? Int J Radiat Oncol Biol Phys (1994) 0.94
Advanced seminoma: the role of chemotherapy and adjunctive surgery. Ann Intern Med (1988) 0.88
Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term followup in 52 patients. J Urol (1987) 0.85
Treatment of seminoma. Semin Oncol (1992) 0.85
[Ambulatory carboplatin monotherapy in advanced seminoma]. Urologe A (1990) 0.80
Current status of chemotherapy in advanced seminoma. Eur J Cancer (1997) 0.79
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08
Uses of barium meal examination in dyspeptic patients under 50. Br Med J (1977) 3.82
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet (2005) 3.75
Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br J Cancer (1992) 3.10
Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol (2003) 3.10
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer (2004) 2.87
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol (2000) 2.55
Rapid diagnosis of testicular tumour. Br J Hosp Med (1992) 2.54
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol (1982) 2.50
Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol (1993) 2.49
Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am (2006) 2.42
Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int (2003) 2.29
A collaborative scheme for tissue typing and matching in renal transplantation. Lancet (1969) 2.26
Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol (1999) 2.25
Is adult-onset coeliac disease due to a low-grade lymphoma of intraepithelial T lymphocytes? Lancet (1991) 2.21
Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol (2010) 2.19
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol (2003) 2.16
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst (1999) 2.15
Prospective study of follow up alone in stage I teratoma of the testis. Br Med J (Clin Res Ed) (1983) 2.13
Perfusion of the spleen with blood containing prostaglandin E1: transmitter liberation and uptake. Proc R Soc Lond B Biol Sci (1969) 2.11
Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol (1995) 2.08
Detection of micrometastases in patients with primary breast cancer. Lancet (1983) 2.07
Randomised consent designs in cancer clinical trials. Eur J Cancer (1995) 2.07
Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer (1984) 2.05
A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer (1991) 1.93
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol (2002) 1.87
Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet (1987) 1.79
Familial testicular cancer in Norway and southern Sweden. Br J Cancer (1996) 1.76
A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer. Clin Oncol (R Coll Radiol) (2007) 1.75
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer (2005) 1.75
Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy. Br J Cancer (2000) 1.74
Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment. Clin Oncol (R Coll Radiol) (2006) 1.74
Rare cancers and specialist centres. Br Med J (Clin Res Ed) (1986) 1.73
Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol (1992) 1.73
The growing teratoma syndrome. Br J Urol (1991) 1.72
DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet (2002) 1.68
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed) (1983) 1.67
A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin Radiol (1987) 1.67
Intensity modulated radiation therapy: a clinical review. Br J Radiol (2000) 1.62
Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol (1992) 1.61
The noradrenaline content of the vas deferens of the guinea-pig. Proc R Soc Lond B Biol Sci (1970) 1.58
Survival prospects after screen-detection of prostate cancer. BJU Int (2002) 1.58
CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol (2000) 1.55
Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer (1997) 1.55
Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol (2000) 1.54
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol (2007) 1.52
Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol (1985) 1.51
Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol (2003) 1.49
A randomized study of the use of a customized immobilization system in the treatment of prostate cancer with conformal radiotherapy. Radiother Oncol (2000) 1.49
Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol (2001) 1.49
Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. Radiother Oncol (1997) 1.47
The continued value of central histopathological review of testicular tumours. Histopathology (2005) 1.46
Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. Clin Oncol (R Coll Radiol) (2001) 1.46
Use of antisera to epithelial membrane antigen for the cytodiagnosis of malignancy in serous effusions. J Clin Pathol (1981) 1.46
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood (1992) 1.45
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Comparison of treatment techniques for conformal radiotherapy of the prostate using dose-volume histograms and normal tissue complication probabilities. Radiother Oncol (1995) 1.43
Angio-immunoblastic lymphadenopathy: report of ten cases and review of the literature. Q J Med (1979) 1.42
RAPPER: the radiogenomics of radiation toxicity. Clin Oncol (R Coll Radiol) (2013) 1.42
Bilateral testicular germ cell tumours: an increasing incidence and prevention by chemotherapy. Br J Urol (1988) 1.42
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial. Clin Oncol (R Coll Radiol) (2008) 1.42
Carcinosarcoma of the ovary. Br J Cancer (2003) 1.41
Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. Ann Oncol (2013) 1.41
A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother Oncol (2001) 1.40
A phase II trial of preoperative mitomycin, cisplatin and 5-fluorouracil in adenocarcinoma of the oesophagus. Clin Oncol (R Coll Radiol) (1998) 1.40
Evaluation of radiotherapy and/or surgicopathological staging after chemotherapy in the management of metastatic germ cell tumours. Br J Urol (1983) 1.40
The management of superficial bladder cancer: an interactive seminar. Br J Urol (1996) 1.40
The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol (2001) 1.40
Ondansetron in the control of refractory emesis following radiotherapy. Clin Oncol (R Coll Radiol) (1992) 1.40
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol (1986) 1.40
Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int J Radiat Oncol Biol Phys (1999) 1.39
The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study. Clin Oncol (R Coll Radiol) (1997) 1.39
Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer (1981) 1.39
Determination of pre-orchiectomy serum levels of alpha-fetoprotein and human choriogonadotrophin in testicular cancer. Br J Urol (1992) 1.39
Developing new drugs for cancer. BMJ (1991) 1.39
Thirty years of Medical Research Council randomized trials in solid tumours. Clin Oncol (R Coll Radiol) (1997) 1.38